
Yaotang Wang
Examiner (ID: 17312, Phone: (571)272-4023 , Office: P/2474 )
| Most Active Art Unit | 2474 |
| Art Unit(s) | 2409, 2419, 3619, 2474 |
| Total Applications | 556 |
| Issued Applications | 416 |
| Pending Applications | 64 |
| Abandoned Applications | 95 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 17865426
[patent_doc_number] => 20220288161
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-09-15
[patent_title] => TSG6 POLYPEPTIDE FRAGMENT FOR DRY EYE DISEASE
[patent_app_type] => utility
[patent_app_number] => 17/597802
[patent_app_country] => US
[patent_app_date] => 2020-06-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13319
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 8
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17597802
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/597802 | TSG6 POLYPEPTIDE FRAGMENT FOR DRY EYE DISEASE | Jun 22, 2020 | Pending |
Array
(
[id] => 16360984
[patent_doc_number] => 20200317735
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-10-08
[patent_title] => BETA-HAIRPIN PEPTIDOMIMETICS AS SELECTIVE ELASTASE INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 16/904920
[patent_app_country] => US
[patent_app_date] => 2020-06-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9065
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16904920
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/904920 | BETA-HAIRPIN PEPTIDOMIMETICS AS SELECTIVE ELASTASE INHIBITORS | Jun 17, 2020 | Abandoned |
Array
(
[id] => 20413013
[patent_doc_number] => 12496275
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-12-16
[patent_title] => Drug delivery methods and compositions
[patent_app_type] => utility
[patent_app_number] => 17/618389
[patent_app_country] => US
[patent_app_date] => 2020-06-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 28
[patent_figures_cnt] => 60
[patent_no_of_words] => 26213
[patent_no_of_claims] => 22
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 14
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17618389
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/618389 | Drug delivery methods and compositions | Jun 15, 2020 | Issued |
Array
(
[id] => 16310867
[patent_doc_number] => 20200289605
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-09-17
[patent_title] => COMPOSITION FOR IMPROVING OR PREVENTING NONALCOHOLIC FATTY LIVER
[patent_app_type] => utility
[patent_app_number] => 16/889367
[patent_app_country] => US
[patent_app_date] => 2020-06-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 3495
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => 0
[patent_words_short_claim] => 125
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16889367
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/889367 | Composition for improving or preventing nonalcoholic fatty liver | May 31, 2020 | Issued |
Array
(
[id] => 16482343
[patent_doc_number] => 20200375943
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-12-03
[patent_title] => CYTOCIDAL METHOD OF CANCER CELLS SELECTIVELY IN HUMAN PATIENTS CLINICALLY BY DEPLETION OF L-ASCORBIC ACID, PRIMARILY, WITH ITS SUPPLEMENTATION ALTERNATELY AUGMENTING ITS CYTOCIDAL EFFECT
[patent_app_type] => utility
[patent_app_number] => 16/886749
[patent_app_country] => US
[patent_app_date] => 2020-05-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11710
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 73
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16886749
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/886749 | CYTOCIDAL METHOD OF CANCER CELLS SELECTIVELY IN HUMAN PATIENTS CLINICALLY BY DEPLETION OF L-ASCORBIC ACID, PRIMARILY, WITH ITS SUPPLEMENTATION ALTERNATELY AUGMENTING ITS CYTOCIDAL EFFECT | May 27, 2020 | Abandoned |
Array
(
[id] => 17828456
[patent_doc_number] => 20220265760
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-08-25
[patent_title] => LEUPROLIDE ACETATE COMPOSITIONS AND METHODS OF USING THE SAME TO TREAT BREAST CANCER
[patent_app_type] => utility
[patent_app_number] => 17/614312
[patent_app_country] => US
[patent_app_date] => 2020-05-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18031
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -24
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17614312
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/614312 | Leuprolide acetate compositions and methods of using the same to treat breast cancer | May 25, 2020 | Issued |
Array
(
[id] => 16437076
[patent_doc_number] => 20200354402
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-11-12
[patent_title] => PEPTIDE COMPOSITIONS AND RELATED METHODS
[patent_app_type] => utility
[patent_app_number] => 16/882660
[patent_app_country] => US
[patent_app_date] => 2020-05-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 2953
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16882660
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/882660 | PEPTIDE COMPOSITIONS AND RELATED METHODS | May 24, 2020 | Abandoned |
Array
(
[id] => 16512923
[patent_doc_number] => 20200392181
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-12-17
[patent_title] => PEPTIDE COMPOSITIONS AND RELATED METHODS
[patent_app_type] => utility
[patent_app_number] => 16/882656
[patent_app_country] => US
[patent_app_date] => 2020-05-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 2956
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16882656
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/882656 | PEPTIDE COMPOSITIONS AND RELATED METHODS | May 24, 2020 | Abandoned |
Array
(
[id] => 17749633
[patent_doc_number] => 20220227837
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-07-21
[patent_title] => IL-2 COMPOSITIONS AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/609638
[patent_app_country] => US
[patent_app_date] => 2020-05-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 32156
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -67
[patent_words_short_claim] => 149
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17609638
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/609638 | IL-2 COMPOSITIONS AND METHODS OF USE THEREOF | May 20, 2020 | Pending |
Array
(
[id] => 17792050
[patent_doc_number] => 20220251141
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-08-11
[patent_title] => IMMUNOMODULATORS
[patent_app_type] => utility
[patent_app_number] => 17/612915
[patent_app_country] => US
[patent_app_date] => 2020-05-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22172
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 522
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17612915
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/612915 | IMMUNOMODULATORS | May 20, 2020 | Pending |
Array
(
[id] => 16297780
[patent_doc_number] => 20200283503
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-09-10
[patent_title] => CD44V6-DERIVED CYCLIC PEPTIDES FOR TREATING CANCERS AND ANGIOGENESIS RELATED DISEASES
[patent_app_type] => utility
[patent_app_number] => 16/878872
[patent_app_country] => US
[patent_app_date] => 2020-05-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 24669
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -56
[patent_words_short_claim] => 257
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16878872
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/878872 | CD44V6-DERIVED CYCLIC PEPTIDES FOR TREATING CANCERS AND ANGIOGENESIS RELATED DISEASES | May 19, 2020 | Abandoned |
Array
(
[id] => 17719089
[patent_doc_number] => 20220211808
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-07-07
[patent_title] => HAPTOGLOBIN FOR USE IN TREATING AN ADVERSE SECONDARY NEUROLOGICAL OUTCOME FOLLOWING A HAEMORRHAGIC STROKE
[patent_app_type] => utility
[patent_app_number] => 17/595390
[patent_app_country] => US
[patent_app_date] => 2020-05-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 28535
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -36
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17595390
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/595390 | HAPTOGLOBIN FOR USE IN TREATING AN ADVERSE SECONDARY NEUROLOGICAL OUTCOME FOLLOWING A HAEMORRHAGIC STROKE | May 14, 2020 | Pending |
Array
(
[id] => 17685912
[patent_doc_number] => 20220193204
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-23
[patent_title] => USES OF A2 DOMAIN OF VON WILLEBRAND FACTOR
[patent_app_type] => utility
[patent_app_number] => 17/595245
[patent_app_country] => US
[patent_app_date] => 2020-05-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 28649
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -45
[patent_words_short_claim] => 42
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17595245
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/595245 | USES OF A2 DOMAIN OF VON WILLEBRAND FACTOR | May 13, 2020 | Pending |
Array
(
[id] => 17719138
[patent_doc_number] => 20220211857
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-07-07
[patent_title] => POLYPEPTIDE DERIVATIVE AND PREPARATION METHOD THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/610606
[patent_app_country] => US
[patent_app_date] => 2020-05-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8102
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 63
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17610606
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/610606 | POLYPEPTIDE DERIVATIVE AND PREPARATION METHOD THEREOF | May 7, 2020 | Pending |
Array
(
[id] => 17734715
[patent_doc_number] => 20220220174
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-07-14
[patent_title] => BNIP3 PEPTIDES FOR TREATMENT OF REPERFUSION INJURY
[patent_app_type] => utility
[patent_app_number] => 17/608655
[patent_app_country] => US
[patent_app_date] => 2020-05-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13420
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 40
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17608655
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/608655 | BNIP3 peptides for treatment of reperfusion injury | May 7, 2020 | Issued |
Array
(
[id] => 17858544
[patent_doc_number] => 11439682
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-09-13
[patent_title] => Treating IgE-mediated allergic diseases
[patent_app_type] => utility
[patent_app_number] => 16/862512
[patent_app_country] => US
[patent_app_date] => 2020-04-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 8
[patent_figures_cnt] => 8
[patent_no_of_words] => 24773
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 215
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16862512
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/862512 | Treating IgE-mediated allergic diseases | Apr 28, 2020 | Issued |
Array
(
[id] => 17968253
[patent_doc_number] => 11485767
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-11-01
[patent_title] => Multivalent PD-L1 binding compounds for treating cancer
[patent_app_type] => utility
[patent_app_number] => 16/860637
[patent_app_country] => US
[patent_app_date] => 2020-04-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 22
[patent_figures_cnt] => 22
[patent_no_of_words] => 18908
[patent_no_of_claims] => 16
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 72
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16860637
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/860637 | Multivalent PD-L1 binding compounds for treating cancer | Apr 27, 2020 | Issued |
Array
(
[id] => 17028562
[patent_doc_number] => 11090360
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-08-17
[patent_title] => Applications of mussel adhesive protein product in treatment and prevention of diseases related to melanin
[patent_app_type] => utility
[patent_app_number] => 16/859458
[patent_app_country] => US
[patent_app_date] => 2020-04-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7553
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 46
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16859458
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/859458 | Applications of mussel adhesive protein product in treatment and prevention of diseases related to melanin | Apr 26, 2020 | Issued |
Array
(
[id] => 16221388
[patent_doc_number] => 20200246504
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-08-06
[patent_title] => PREPARATION AND/OR FORMULATION OF PROTEINS CROSS-LINKED WITH POLYSACCHARIDES
[patent_app_type] => utility
[patent_app_number] => 16/856031
[patent_app_country] => US
[patent_app_date] => 2020-04-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21611
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 73
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16856031
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/856031 | Preparation and/or formulation of proteins cross-linked with polysaccharides | Apr 22, 2020 | Issued |
Array
(
[id] => 17911395
[patent_doc_number] => 20220313790
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-10-06
[patent_title] => HUMAN ALBUMIN-CONTAINING MEDICAL PRODUCT AND PREPARATION METHOD THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/642239
[patent_app_country] => US
[patent_app_date] => 2020-04-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8624
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17642239
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/642239 | HUMAN ALBUMIN-CONTAINING MEDICAL PRODUCT AND PREPARATION METHOD THEREOF | Apr 21, 2020 | Pending |